Sanofi Genzyme sponsors and administers the Pompe disease registry (NCT00231400), which it launched in 2001 and is expected to run through 2034. It is the largest patient registry dedicated to this rare disorder, which affects about 1 in 40,000 people in the U.S.
Sanofi designed the global and observational registry to collect clinical data about the identification, onset, progression, and treatment course of Pompe disease across up to 2,000 patients. Participants are not given any new or experimental therapies, and it is not necessary to be on treatment to take part in this registry.
What are the registry’s goals?
Set up to record natural history, treatments, and clinical outcomes across people with Pompe disease, the registry has four aims:
- Help improve understanding of the course of Pompe disease
- Help develop care recommendations
- Learn more about those who develop the disease
- Gather more information about different treatments for Pompe, including Lumizyme (alglucosidase alfa), an enzyme replacement therapy (ERT) by Sanofi. Lumizyme is the first ERT for Pompe disease approved by the U.S. Food and Drug Administration (FDA).
Who can participate in the Pompe disease registry?
A doctor can enroll a child with a confirmed Pompe disease diagnosis in the registry; patients and families cannot enroll directly. Participation is voluntary, but those enrolled cannot be taking part in another Sanofi clinical trial.
How does the registry work?
Your child will continue receiving care and treatment as usual from their physician, who will send information gathered at these care visits to the registry.
The Pompe disease registry recommends that doctors perform a certain number of evaluations, like weight, blood pressure, chest X-rays and heart tests, and blood and urine tests, at regular intervals (every three or so months). Patients and families will also be asked to complete quality of life questionnaires.
If your child is using Lumizyme, the doctor will also regularly take blood samples and monitor levels of antibodies.
How might the registry help my child?
The registry permits communication and information sharing among clinicians and other Pompe specialists, which could result in a better standard of care for your child and others with this disease. Information from this study aims to help improve the diagnosis, treatment, and management of Pompe disease.
What about privacy?
The registry protects the confidentiality of your child’s information, assigning them a unique identification number. It does not collect any patient names.
Ask your child’s doctor if your child can participate in the registry; you may not enroll your child on your own. The registry will document the care given and assessments made during their routine treatment.
Last updated: May 11, 2020
Pompe Disease News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?